http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007136602-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 |
| filingDate | 2006-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007136602-A |
| titleOfInvention | APPLICATION OF S1P RECEPTOR MODULATORS IN OPHTHALMOLOGY |
| abstract | 1. The use of an S1P receptor agonist for the manufacture of a medicament for the treatment of ocular disorders. ! 2. The use according to claim 1, wherein said eye disorder is selected from the group consisting of ischemic retinopathy, ischemic neuropathy of the anterior optic nerve, all forms of optic neuritis, age-related macular degeneration (AMD), dry form (dry AMD) and weeping form (weeping AMD), diabetic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), cystic macular edema (CME), retinal detachment, retinitis pigmentosa (RP), Stargardt syndrome, macular degeneration ( Best disease), Leber's congenital amaurosis and other hereditary retinal degeneration, pathological myopia, retroletal fibroplasia, Leber’s hereditary optic neuropathy, consequences of corneal transplantation or corneal refractive surgery, dry keratoconjunctivitis (KCS) or dry keratitis and herpetitis. ! 3. The use according to any one of claims 1 or 2, wherein the S1P receptor agonist means or includes a group of formula X! ! where Z is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, phenyl, phenyl substituted with an OH group, C1-C6 alkyl substituted with 1-3 substituents selected from the group consisting of halogen, C3-C8 cycloalkyl, phenyl and phenyl, substituted by OH, or CH2-R4z, where R4z is OH, acyloxy, or a residue of formula (a)! ! where Z1 is a single bond or O, preferably O, each of R5z and R6z independently is H or C1-C4 alkyl optionally substituted with 1, 2 or 3 halogen atoms,! R1z means OH, acyloxy or a residue of formula (a), and each of R2z and R3z is independently |
| priorityDate | 2005-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.